Health technology assessement of the fxed combination of insulin glargine 100 UI/ml and lixisenatide in the treatment intensifcation of diabetes mellitus type 2
Fixed antidiabetic drugs’ combinations have aim to improve of Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control of fasting and prandial glucose levels, contained insulin glargine 100 UI/ml and lixisenatide. In the...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Russo |
| Έκδοση: |
Izdatelstvo OKI
2019-01-01
|
| Σειρά: | Качественная клиническая практика |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.clinvest.ru/jour/article/view/413 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|